WHO ICTRP trial
A Phase II, Single-center, Single-arm trial to evaluate the efficacy of…
KCT0006951 · Clinical Research Information Service (CRIS) · Not Recruiting
Key facts
| Trial ID | KCT0006951 |
|---|---|
| Public title | A Phase II, Single-center, Single-arm trial to evaluate the efficacy of lazertinib in treatment-naive patients for EGFR mutated non-small cell lung cancer with symptomatic or asymptomatic brain metastasis |
| Scientific title | A Phase II, Single-center, Single-arm trial to evaluate the efficacy of lazertinib in treatment-naive patients for EGFR mutated non-small cell lung cancer with symptomatic or asymptomatic brain metastasis |
| Primary sponsor | Asan Medical Center |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Not Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : The lazertinib arms will take lazertinib during the clinical trial period. The amount of lazertinib is 240mg per day, orally. The subjects should continue taking the investigational drugs during the clinical trial periods until… |
| Registration date | Jan 21, 2022 |
| Target size | 75 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: